Caffeine / α-SMA Cancer Research Results

Caff, Caffeine: Click to Expand ⟱

Features:

Caffeine is a natural chemical with stimulant effects. It is found in coffee, tea, cola, cocoa, guarana, yerba mate, and over 60 other products.

Caffeine (CAF; 1,3,7-trimethylxanthine) — dietary methylxanthine (natural product / drug) found in coffee/tea/cacao and used in OTC stimulants and some analgesic combinations. Sources: coffee/tea, supplements, OTC meds.

Primary mechanisms (conceptual rank):
1) Adenosine receptor antagonism (A1/A2A) → wakefulness, neuromodulation
2) ↑ Catecholamines / CNS arousal → performance + mood effects
3) PDE inhibition (cAMP/cGMP ↑) (high concentration only)
4) Cell-cycle checkpoint interference (ATM/ATR-related) (high concentration only)

Bioavailability / PK relevance: Rapid oral absorption; widely distributed (including CNS); hepatic metabolism (CYP1A2) with large inter-individual variability; tolerance develops with habitual use.

In-vitro vs oral exposure: Many “anti-cancer” mechanisms rely on supra-physiologic concentrations (PDE inhibition, checkpoint override) vs typical dietary plasma levels; clinically relevant mechanism is adenosine antagonism. This is a major translation constraint. Physiologic human exposures after ordinary intake are in the low micromolar range relevant to adenosine receptor occupancy, whereas many anticancer in-vitro effects commonly attributed to caffeine, especially PDE inhibition, Ca²⁺ release, and checkpoint override, usually require far higher concentrations, often approaching high-micromolar to millimolar ranges.

Clinical evidence status: Extensive human data for alertness/performance; oncology evidence is mainly epidemiologic + preclinical (no anticancer indication).

Natural stimulant

-Caffeine appears to interact with several pathways relevant to cancer biology—including adenosine receptor signaling, DNA damage response, cell cycle regulation, apoptosis, PI3K/Akt/mTOR, and NF-κB
—Its overall impact likely depends on the cancer type, stage, microenvironment, and the dosage administered

Caffeine — Cancer vs Normal Cell Pathway Map

Rank	Pathway / Axis	Cancer Cells	Normal Cells	TSF	Primary Effect	Notes / Interpretation
1	Adenosine signaling (A1/A2A antagonism)	↓ adenosine-mediated suppression (context-dependent)	↑ arousal/neuromodulation	P/R	Immune + signaling tone shift	A2A antagonism can be immunostimulatory in tumor-microenvironment contexts; not a tumor-directed cytotoxin and highly context-dependent.
2	cAMP signaling / catecholamine tone	↔ (context-dependent)	↑ (acute stimulation)	P/R	Systemic stimulation	Stress-hormone effects can be bidirectional for cancer biology depending on context; not a central anticancer mechanism.
3	DNA damage response checkpoints (ATM/ATR)	↓ checkpoints (high concentration only)	↓ checkpoints (high concentration only)	P/R	S/G2 checkpoint override	Classic in vitro effect used to radiosensitize/chemosensitize; translation limited by concentration requirements.
4	Cell cycle / proliferation	↓ or ↔ (model-dependent; high concentration only)	↔	R/G	Cytostatic effects (experimental)	Observed in vitro; not consistent at dietary exposures.
5	Apoptosis	↑ (high concentration only)	↔	R/G	Experimental cytotoxicity	Typically downstream of checkpoint disruption/ROS stress in vitro.
6	PDE inhibition	↑ cAMP/cGMP (high concentration only)	↑ cAMP/cGMP (high concentration only)	P/R	Second-messenger amplification	PDE inhibition is not dominant at typical intake; becomes relevant only at higher exposures.
7	ROS	↔ / ↑ (high concentration only)	↔	P/R	Not a primary redox drug	Some models show oxidative stress at high dose; not canonical at physiologic exposure.
8	NRF2	↔	↔	R/G	No primary modulation	Not a canonical caffeine-first axis.
9	HIF-1α	↔ (limited; model-dependent)	↔	G	Not primary	Any hypoxia-pathway effects are indirect and not robustly classed as core.
10	Ferroptosis	↔ (not established)	↔	R/G	Not canonical	No consistent ferroptosis program attributed to caffeine.
11	Ca²⁺ signaling	↔	↔	P/R	No primary role	Not a dominant mechanistic axis at typical intake.
12	Clinical Translation Constraint	↓ (constraint)	↓ (constraint)	—	Exposure + tolerance + sleep effects	Most tumor-directed mechanisms require high concentrations; chronic use limited by sleep disruption/anxiety in susceptible individuals and tolerance to stimulant effects.

TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr

Caffeine — AD relevance: Strong mechanistic fit via adenosine A2A antagonism (synaptic plasticity + neuroinflammation modulation). Human data support acute attention benefits; dementia/AD risk signals are largely observational (not disease-modifying approval).

Primary mechanisms (conceptual rank):
1) A2A antagonism → ↑ synaptic efficiency / plasticity
2) ↓ Neuroinflammation (microglial tone; cytokine signaling) (context-dependent)
3) ↓ Aβ/tau-associated toxicity pathways (preclinical; model-dependent)
4) Cerebrovascular / glymphatic-sleep tradeoffs (alertness vs sleep architecture effects)

Bioavailability / PK relevance: Rapid CNS penetration; effects are acute (minutes–hours) but chronic patterns depend on tolerance and sleep timing.

Clinical evidence status: Supportive (symptom/attention); AD disease-modifying efficacy not established.

Caffeine — AD / Neurodegeneration Pathway Map

Rank	Pathway / Axis	Cells	TSF	Primary Effect	Notes / Interpretation
1	Adenosine A2A antagonism (synaptic plasticity)	↑	P/R	Improved signaling efficiency	Core neuro mechanism; overlaps with the rationale for A2A antagonists in neurodegeneration frameworks.
2	Neuroinflammation (microglial activation; cytokines)	↓ (context-dependent)	R/G	Lower inflammatory stress	Often attributed to adenosine-pathway modulation; magnitude is model- and state-dependent.
3	ROS / mitochondrial stress	↔ / ↓ (supportive)	P/R	Resilience support (secondary)	Not a primary antioxidant; changes are typically indirect via signaling state and inflammation.
4	Aβ / tau-associated pathology	↔ / ↓ (preclinical; model-dependent)	G	Reduced proteotoxic stress (hypothesis)	Evidence is stronger in models than in biomarker-confirmed human AD studies.
5	Ca²⁺ excitotoxicity interplay	↔ (indirect)	P/R	Not primary	Could be secondary to synaptic modulation; treat as secondary unless explicit Ca²⁺ endpoints exist.
6	Sleep architecture / glymphatic coupling	↑ alertness; ↓ sleep (timing-dependent)	R/G	Tradeoff axis	Potential benefit via daytime function but potential harm if it chronically degrades sleep quality (sleep is relevant to amyloid clearance hypotheses).
7	Clinical Translation Constraint	↓ (constraint)	—	Timing + tolerance + heterogeneity	Benefits depend strongly on dosing/timing and individual sensitivity; not disease-modifying therapy.

TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr

α-SMA, α-smooth muscle actin: Click to Expand ⟱

Source:

Type: protein

α-smooth muscle actin (α-SMA) is a protein that is often associated with cancer progression. It is a key component of the actin cytoskeleton and plays a crucial role in cell migration, invasion, and contraction.
α-SMA is often expressed by cancer-associated fibroblasts (CAFs), which are a type of stromal cell that surrounds the tumor. CAFs expressing α-SMA can promote tumor growth and metastasis.
High levels of α-SMA expression have been correlated with poor prognosis in various types of cancer, including breast, lung, and colorectal cancer.

Scientific Papers found: Click to Expand⟱

1206-

Caff,

Caffeine inhibits TGFβ activation in epithelial cells, interrupts fibroblast responses to TGFβ, and reduces established fibrosis in ex vivo precision-cut lung slices

in-vitro,

NA,

ex-vivo,

NA,

Fibrosis↓, TGF-β↓, α-SMA↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:

Migration ⓘ

Fibrosis↓, 1, TGF-β↓, 1, α-SMA↓, 1,
Total Targets: 3

Pathway results for Effect on Normal Cells:

Total Targets: 0

Scientific Paper Hit Count for: α-SMA, α-smooth muscle actin

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells